Should I buy or sell Trevena stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares. View TRVN analyst ratings or view top-rated stocks .

What is Trevena's stock price target for 2024?

1 analysts have issued 1-year price objectives for Trevena's shares. Their TRVN share price targets range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 2,456.8% from the stock's current price. View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts .

How have TRVN shares performed in 2024?

Trevena's stock was trading at $0.7221 at the start of the year. Since then, TRVN shares have decreased by 51.3% and is now trading at $0.3520. View the best growth stocks for 2024 here .

Are investors shorting Trevena?

Trevena saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 112,800 shares, an increase of 54.5% from the March 15th total of 73,000 shares. Based on an average daily volume of 123,100 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the shares of the company are short sold. View Trevena's Short Interest .

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TRVN earnings forecast .

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) released its earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.60 million. During the same quarter in the previous year, the firm posted ($2.50) EPS.

When did Trevena's stock split?

Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , SCYNEXIS (SCYX) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Aeterna Zentaris (AEZS) , Bionano Genomics (BNGO) and Dynavax Technologies (DVAX) .

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TRVN Stock Alerts

$0.35

-0.01 (-2.76%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.32
▼
$0.36
50-Day Range: $0.35
▼
$0.61
52-Week Range: $0.30
▼
$3.28

Volume: 170,062 shs
Average Volume: 374,859 shs
Market Capitalization: $6.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Trevena alerts:

Trevena MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,456.8% Upside
$9.00 Price Target
Short Interest: Healthy
0.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.24
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.28) to ($0.98) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Trevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Trevena has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.63% of the float of Trevena has been sold short.
Short Interest Ratio / Days to Cover
Trevena has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Trevena has recently increased by 54.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Trevena does not currently pay a dividend.
Dividend Growth
Trevena does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRVN.

2.4

News and Social Media Coverage

News Sentiment
Trevena has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Trevena this week, compared to 1 article on an average week.
Search Interest
4 people have searched for TRVN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevena insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Trevena is held by insiders.
Percentage Held by Institutions
Only 13.56% of the stock of Trevena is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Trevena are expected to grow in the coming year, from ($1.28) to ($0.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trevena is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevena is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Trevena Stock (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

TRVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRVN Stock News Headlines

April 18, 2024 | msn.com

Trevena (TRVN) Price Target Decreased by 7.69% to 6.12

April 14, 2024 | americanbankingnews.com

Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | morningstar.com

Trevena Inc TRVN

April 4, 2024 | msn.com

Danny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In Bulgaria

April 3, 2024 | msn.com

Trevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital Environment

April 2, 2024 | benzinga.com

Recap: Trevena Q4 Earnings

April 1, 2024 | globenewswire.com

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 16, 2024 | msn.com

Trevena Cross cafe reopening as the Palm Tree Bistro

March 8, 2024 | msn.com

The Palm Tree Bistro at Trevena Cross Nurseries reopening

February 22, 2024 | benzinga.com

Trevena Stock (NASDAQ:TRVN), Short Interest Report

January 10, 2024 | msn.com

Trevena files to sell 2.78M shares for holders

December 28, 2023 | finance.yahoo.com

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

December 28, 2023 | finance.yahoo.com

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

December 27, 2023 | msn.com

Trevena announces private placement and warrant exercise

December 27, 2023 | markets.businessinsider.com

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

December 27, 2023 | finance.yahoo.com

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

December 16, 2023 | msn.com

Frank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’

December 15, 2023 | msn.com

Frank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'

December 4, 2023 | finance.yahoo.com

Trevena Awarded OLINVYK Agreement with Premier, Inc.

December 4, 2023 | finance.yahoo.com

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

November 30, 2023 | finance.yahoo.com

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

November 17, 2023 | finance.yahoo.com

Trevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

November 15, 2023 | finance.yahoo.com

Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript

November 14, 2023 | finanznachrichten.de

Trevena, Inc.: Trevena Reports Third Quarter 2023 Results and Provides Business Update

November 14, 2023 | markets.businessinsider.com

Trevena Reports Third Quarter 2023 Results and Provides Business Update

See More Headlines

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2023
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TRVN
CUSIP: N/A
CIK: 1429560
Web: www.trevena.com
Phone: (610) 354-8840
Fax: N/A
Employees: 23
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $9.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +2,456.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,290,000.00
Net Margins: N/A
Pretax Margin: -1,289.25%
Return on Equity: -1,018.15%
Return on Assets: -98.93%

Debt

Debt-to-Equity Ratio: 8.35
Current Ratio: 4.66
Quick Ratio: 4.66

Sales & Book Value

Annual Sales: $3.13 million
Price / Sales: 2.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.44) per share
Price / Book: -0.80

Miscellaneous

Outstanding Shares: 18,321,000
Free Float: 17,881,000
Market Cap: $6.45 million
Optionable: Optionable
Beta: 1.10

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Carrie L. Bourdow (Age 61)
President, CEO & Chairman
Comp: $1M
Mr. Barry Shin (Age 52)
Executive VP, COO & CFO
Comp: $670.02k
Dr. Mark A. Demitrack M.D. (Age 66)
Senior VP & Chief Medical Officer
Comp: $690.32k
Dr. Howard A. Rockman M.D.
Scientific Founder, Consultant and Member of Scientific Advisory Board
Mr. Joel Solomon
VP, General Counsel & Chief Compliance Officer
Mr. Michael Catalano
Vice President of Marketing
Mr. Robert T. Yoder (Age 58)
Senior VP, Chief Business Officer & Head of Commercial Operations
Comp: $490.64k
Ms. Patricia M. Drake (Age 58)
Senior VP & Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TRVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevena stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings or view top-rated stocks.
What is Trevena's stock price target for 2024?: 1 analysts have issued 1-year price objectives for Trevena's shares. Their TRVN share price targets range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 2,456.8% from the stock's current price.
View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts.
How have TRVN shares performed in 2024?: Trevena's stock was trading at $0.7221 at the start of the year. Since then, TRVN shares have decreased by 51.3% and is now trading at $0.3520.
View the best growth stocks for 2024 here.
Are investors shorting Trevena?: Trevena saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 112,800 shares, an increase of 54.5% from the March 15th total of 73,000 shares. Based on an average daily volume of 123,100 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the shares of the company are short sold.
View Trevena's Short Interest.
When is Trevena's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our TRVN earnings forecast.

How were Trevena's earnings last quarter?: Trevena, Inc. (NASDAQ:TRVN) released its earnings results on Monday, May, 15th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.60 million. During the same quarter in the previous year, the firm posted ($2.50) EPS.
When did Trevena's stock split?: Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Trevena own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).
How do I buy shares of Trevena?: Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Trevena (TRVN) Stock Price, News & Analysis

Trevena MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Trevena Stock (NASDAQ:TRVN)

TRVN Stock Price History

TRVN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

TRVN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™